Home Cart Sign in  
Chemical Structure| 1453834-21-3 Chemical Structure| 1453834-21-3

Structure of LDC4297
CAS No.: 1453834-21-3

Chemical Structure| 1453834-21-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LDC4297 is a potent CDK7 selective inhibitor with IC50 of 0.13 ± 0.06 nM.

Synonyms: LDC044297

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LDC4297

CAS No. :1453834-21-3
Formula : C23H28N8O
M.W : 432.52
SMILES Code : CC(C1=C2N(N=C1)C(NCC3=CC=CC=C3N4N=CC=C4)=NC(OC5CNCCC5)=N2)C
Synonyms :
LDC044297
MDL No. :MFCD28411427
InChI Key :LSGRZENCFIIHNV-UHFFFAOYSA-N
Pubchem ID :78161839

Safety of LDC4297

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of LDC4297

Hedgehog

Isoform Comparison

Biological Activity

Target
  • CDK7

    CDK7, IC50:0.13 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Rhesus CMV-infected HFFs 0.018 µM 7 days To evaluate the synergistic antiviral effect of LDC4297 with MBV in the RhCMV model. Results showed that the MBV + LDC4297 combination exhibited synergism in RhCMV. Pharmaceutics. 2023 Nov 27;15(12):2680
Guinea pig embryonic fibroblasts (GPEFs) 0.044 µM 7 days To evaluate the synergistic antiviral effect of LDC4297 with MBV in the GPCMV model. Results showed that the MBV + LDC4297 combination exhibited synergism in GPCMV. Pharmaceutics. 2023 Nov 27;15(12):2680
Human foreskin fibroblasts (HFFs) 0.009 µM 7 days To evaluate the synergistic anti-HCMV effect of LDC4297 with vCDK/pUL97 inhibitors such as MBV, Ax7396, Gö6976, and Vi7392. Results showed significant drug synergism in all four combinations. Pharmaceutics. 2023 Nov 27;15(12):2680
ARPE-19 cells 0.07 μM 7 days Evaluate the inhibitory effect of LDC4297 on HCMV TB40, showing broad-spectrum antiherpesviral activity at nanomolar concentrations. Int J Mol Sci. 2021 Jan 8;22(2):575
Mouse embryonic fibroblasts (MEF) 0.07 μM 5 days Evaluate the inhibitory effect of LDC4297 on MCMV, showing broad-spectrum antiherpesviral activity at nanomolar concentrations. Int J Mol Sci. 2021 Jan 8;22(2):575
Human foreskin fibroblasts (HFF) 0.02 μM 7 days Evaluate the inhibitory effect of LDC4297 on HCMV, showing broad-spectrum antiherpesviral activity at nanomolar concentrations. Int J Mol Sci. 2021 Jan 8;22(2):575
H1975 cells 10 μM 24 hours LDC4297 significantly decreased glucose consumption and GLUT1 mRNA and protein levels in H1975 cells Nat Commun. 2019 Nov 29;10(1):5444
H460 cells 10 μM 24 hours LDC4297 significantly decreased glucose consumption and GLUT1 mRNA and protein levels in H460 cells Nat Commun. 2019 Nov 29;10(1):5444
Panc89 0.05-0.3 μM 3 days To evaluate the effect of LDC4297 on the viability of pancreatic cancer cells, results showed that Panc89 cells exhibited significantly higher sensitivity to LDC4297. Int J Mol Sci. 2022 Jan 12;23(2):812
Mia-Paca2 0.05-0.3 μM 3 days To evaluate the effect of LDC4297 on the viability of pancreatic cancer cells, results showed that Mia-Paca2 cells exhibited intermediate to good sensitivity at low concentrations of LDC4297. Int J Mol Sci. 2022 Jan 12;23(2):812
MCF-7 2.5 and 5 uM 48 hours LDC4297 treatment did not influence the expression of wild-type p53 in ER-positive breast cancer cells Front Oncol. 2021 May 24;11:664848
DU4475 2.5 and 5 uM 48 hours LDC4297 treatment did not influence the expression of wild-type p53 in TNBC cells Front Oncol. 2021 May 24;11:664848
Hs-578T 2.5 and 5 uM 48 hours LDC4297 treatment effectively downregulated p53 expression in TNBC cells with mutant-type p53 Front Oncol. 2021 May 24;11:664848

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Balb/c mice Recombinant MCMV-UL97 infection model Oral (p.o.) LDC4297: 1 mg/kg/d; MBV: 0.1 mg/kg/d Daily administration for 4 days To evaluate the synergistic antiviral effect of MBV + LDC4297 in an in vivo model. Results showed significant synergism of the MBV + LDC4297 combination in vivo. Pharmaceutics. 2023 Nov 27;15(12):2680
Balb/c mice MCMV infection model Oral gavage 20 mg/kg/d Once daily for 5 days Evaluate the in vivo inhibitory effect of LDC4297 on MCMV, showing significant reduction in viral load. Int J Mol Sci. 2021 Jan 8;22(2):575

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.31mL

0.46mL

0.23mL

11.56mL

2.31mL

1.16mL

23.12mL

4.62mL

2.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories